These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1371563)

  • 21. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
    Andros EA; Danesghari F; Crawford ED
    Clin Invest Med; 1993 Dec; 16(6):510-5. PubMed ID: 7516835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for prostatic carcinoma with prostate specific antigen.
    Brawer MK; Chetner MP; Beatie J; Buchner DM; Vessella RL; Lange PH
    J Urol; 1992 Mar; 147(3 Pt 2):841-5. PubMed ID: 1371559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer in nonurological patients with normal prostates on digital rectal examination.
    Hammerer P; Loy V; Dieringer J; Huland H
    J Urol; 1992 Mar; 147(3 Pt 2):833-6. PubMed ID: 1371557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
    Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
    J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
    Sato N; Kotake T; Masai M; Sakai S; Ito H
    Hinyokika Kiyo; 2000 Jan; 46(1):1-7. PubMed ID: 10723656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
    Kawai K; Akaza H
    Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues.
    Sundkvist GM; Björk T; Kjellström H; Lilja B
    Scand J Urol Nephrol; 1996 Feb; 30(1):29-32. PubMed ID: 8727862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
    Oesterling JE; Andrews PE; Suman VJ; Zincke H; Myers RP
    J Urol; 1993 Apr; 149(4):779-82. PubMed ID: 7681117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of gonadotrophin-releasing hormone analogues in the management of prostate cancer.
    Gallagher CJ
    Clin Oncol (R Coll Radiol); 1992 May; 4(3):137-8. PubMed ID: 1586629
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D
    J Urol; 2003 May; 169(5):1738-41. PubMed ID: 12686821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients.
    Kaczmarek P; Pokoca L; Niemirowicz J; Majewska E; Baj Z
    Pharmacol Rep; 2008; 60(3):399-403. PubMed ID: 18622065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
    Catalona WJ; Smith DS; Ratliff TL; Dodds KM; Coplen DE; Yuan JJ; Petros JA; Andriole GL
    N Engl J Med; 1991 Apr; 324(17):1156-61. PubMed ID: 1707140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer.
    Giraud B
    J Int Med Res; 1990; 18 Suppl 1():84-9. PubMed ID: 1691113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.